Merck & Co., Inc. $MRK Shares Bought by Strengthening Families & Communities LLC

Strengthening Families & Communities LLC raised its position in Merck & Co., Inc. (NYSE:MRK) by 12.0% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 47,767 shares of the company’s stock after buying an additional 5,125 shares during the quarter. Merck & Co., Inc. comprises about 1.8% of Strengthening Families & Communities LLC’s holdings, making the stock its 15th largest position. Strengthening Families & Communities LLC’s holdings in Merck & Co., Inc. were worth $5,028,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of MRK. Barnes Dennig Private Wealth Management LLC increased its stake in Merck & Co., Inc. by 302.3% in the 3rd quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock valued at $30,000 after buying an additional 266 shares during the period. United Financial Planning Group LLC acquired a new position in Merck & Co., Inc. in the 3rd quarter valued at $31,000. Wealth Watch Advisors INC acquired a new position in Merck & Co., Inc. in the 3rd quarter valued at $34,000. Dunhill Financial LLC increased its stake in Merck & Co., Inc. by 83.0% in the 3rd quarter. Dunhill Financial LLC now owns 419 shares of the company’s stock valued at $35,000 after buying an additional 190 shares during the period. Finally, Silicon Valley Capital Partners increased its stake in Merck & Co., Inc. by 160.5% in the 3rd quarter. Silicon Valley Capital Partners now owns 422 shares of the company’s stock valued at $35,000 after buying an additional 260 shares during the period. 76.07% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. Wolfe Research raised shares of Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 price target on the stock in a research note on Thursday, January 8th. Guggenheim upped their price target on shares of Merck & Co., Inc. from $122.00 to $140.00 and gave the stock a “buy” rating in a research note on Friday, February 6th. Wells Fargo & Company lowered their price target on shares of Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. Barclays assumed coverage on shares of Merck & Co., Inc. in a research note on Friday, February 20th. They set an “overweight” rating and a $140.00 price target on the stock. Finally, TD Cowen upped their price target on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the stock a “hold” rating in a research note on Tuesday, January 20th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $128.18.

Insider Transactions at Merck & Co., Inc.

In related news, CMO Chirfi Guindo sold 10,000 shares of the stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $118.41, for a total value of $1,184,100.00. Following the sale, the chief marketing officer directly owned 70,615 shares of the company’s stock, valued at approximately $8,361,522.15. This represents a 12.40% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jennifer Zachary sold 121,573 shares of the stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the completion of the sale, the executive vice president directly owned 68,916 shares in the company, valued at approximately $8,211,341.40. The trade was a 63.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.17% of the stock is currently owned by corporate insiders.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck published a Science paper describing a scalable, enzyme-driven synthesis for its investigational oral PCSK9 inhibitor enlicitide decanoate — a notable R&D milestone that supports the commercial potential of a new oral lipid-lowering modality. Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate
• Positive Sentiment: Merck’s BioReliance unit inked a five?year deal to be the sole testing provider for Genetix Biotherapeutics’ FDA?approved gene therapies — adds recurring, commercial?stage service revenue and reinforces Merck’s role in cell & gene therapy commercialization. Merck Becomes Sole Testing Provider for Genetix Biotherapeutics’ FDA-Approved Gene Therapies
• Positive Sentiment: Merck completed the Terns acquisition to expand its chronic myeloid leukemia (CML) pipeline; the deal and FDA breakthrough designation for a TERN asset strengthen oncology pipeline optionality. MSD concludes Terns acquisition to expand CML pipeline
• Positive Sentiment: Analysts and brokers showed support after Merck’s Q1 beat — one analyst nudged the price target higher and BMO reiterated a buy — giving near?term fundamental backing to the stock. Analyst Raises Merck (MRK) Price Target by $1 After Beating Q1 Estimates BMO Capital Remains a Buy on Merck & Company (MRK)
• Neutral Sentiment: Merck Animal Health selected Salesforce’s Agentforce Life Sciences for omnichannel engagement — a strategic IT/customer?engagement win but with modest near?term financial impact versus drug/cell?therapy drivers. Salesforce AI Win With Merck Highlights Real World Platform Adoption
• Neutral Sentiment: Citigroup initiated coverage with a “neutral” rating and a $125 price target — supportive of upside but not a strong buy signal; highlights mixed analyst views on valuation vs. growth. Citigroup Initiates Coverage
• Negative Sentiment: Sector competitors posted robust oncology and diabetes results (J&J oncology growth; Eli Lilly’s blockbuster Mounjaro sales), underscoring competitive pressure in key therapeutic areas and possibly contributing to profit?taking and relative valuation compression for Merck. Sector Competitive Moves Darzalex, Erleada & New Drugs Keep J&J’s Oncology Engine Charged in Q1 Eli Lilly Now Has the World’s Best-Selling Drug — But Does That Make the Stock a No-Brainer Buy?

Merck & Co., Inc. Stock Performance

NYSE:MRK opened at $112.22 on Friday. The company has a quick ratio of 1.30, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $125.14. The stock has a market cap of $277.17 billion, a PE ratio of 31.61, a price-to-earnings-growth ratio of 2.56 and a beta of 0.18. The firm’s fifty day simple moving average is $117.07 and its 200-day simple moving average is $108.31.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business had revenue of $16.29 billion for the quarter, compared to analysts’ expectations of $15.85 billion. During the same period in the prior year, the company posted $2.22 EPS. The business’s revenue for the quarter was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Analysts expect that Merck & Co., Inc. will post 5.16 earnings per share for the current fiscal year.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.